Profile picture

Professor Gabriele Giacomo Schiattarella

Charite University Hospital, Berlin (Germany)
Follow
Biography
Gabriele Schiattarella is a cardiologist-scientist whose research focuses on molecular mechanisms of remodeling in the disease-stressed myocardium. He received his MD in 2009 from the University Federico II of Naples (Italy). After completing a fellowship in Cardiology at the same university (2015) and matriculating in a PhD program in Experimental Medicine, he moved to University of Texas Southwestern Medical Center in Dallas, Texas, USA where he completed his PhD program and currently serve as researcher. Gabriele’s background is in medicine, experimental cardiology and cellular/molecular biology, with specific training and expertise in murine models of cardiovascular disease and preclinical assessment of cardiovascular function. His research interests include molecular mechanisms of cardiac hypertrophy and heart failure (HFpEF and HFrEF); mitochondrial dysfunction, reactive oxygen species production and nitrosative stress in cardiomyocytes as well as regulation of protein quality
Logo ESC

Contributor content

Module C: Mechanisms of cardiovascular disease - Heart Failure
Session
Module C: Mechanisms of cardiovascular disease - Heart Failure
13 June 2026
Metabolic, immune, and cellular drivers of HFpEF pathogenesis and progression
Session
Metabolic, immune, and cellular drivers of HFpEF pathogenesis and progression
31 August 2025
Therapeutic advances in cardiometabolic HFpEF: pharmacotherapy and lifestyle intervention
Session
Therapeutic advances in cardiometabolic HFpEF: pharmacotherapy and lifestyle intervention
31 August 2025
The floor is yours: bring your questions on management of cardiovascular-kidney-metabolic syndrome
Session
The floor is yours: bring your questions on management of cardiovascular-kidney-metabolic syndrome
30 August 2025
Mechanisms of cardiomyopathy and heart failure: from fibroblast dynamics to metabolic remodelling
Session
Mechanisms of cardiomyopathy and heart failure: from fibroblast dynamics to metabolic remodelling
29 August 2025
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
29 August 2025
The cardiometabolic syndrome and extracardiac drug effects beneficial to the heart
Session
The cardiometabolic syndrome and extracardiac drug effects beneficial to the heart
21 January 2025
Chronic heart failure - epidemiology, prognosis, outcome 7
Session
Chronic heart failure - epidemiology, prognosis, outcome 7
21 May 2023
Valvular heart disease
Session
Valvular heart disease
20 May 2023
Multi-omics for personalised medicine
Session
Multi-omics for personalised medicine
17 March 2023

ESC 365 is supported by